Genomma Lab InternacionalB de CV (Genomma Lab InternacionalB de CV) 5-Year EBITDA Growth Rate : 5.80% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV 5-Year EBITDA Growth Rate?

Genomma Lab InternacionalB de CV's EBITDA per Share for the three months ended in Mar. 2024 was $0.05.

During the past 12 months, Genomma Lab InternacionalB de CV's average EBITDA Per Share Growth Rate was -7.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 1.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Genomma Lab InternacionalB de CV was 53.00% per year. The lowest was -1.10% per year. And the median was 10.20% per year.

Competitive Comparison of Genomma Lab InternacionalB de CV's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomma Lab InternacionalB de CV's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's 5-Year EBITDA Growth Rate falls into.

Genomma Lab InternacionalB de CV 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Genomma Lab InternacionalB de CV (OTCPK:GNMLF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Genomma Lab InternacionalB de CV 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomma Lab InternacionalB de CV (Genomma Lab InternacionalB de CV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

LABB:Mexico GEKA:Germany

Address

Avenida Antonio Dovalí Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210

Website

https://www.genommalab.com

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.